Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer (PHOEBE): A Multicentre, Open-Label, Randomised, Controlled, Phase 3 TrialLancet Oncol 2021 Feb 11;[EPub Ahead of Print], B Xu, M Yan, F Ma, X Hu, J Feng, Q Ouyang, Z Tong, H Li, Q Zhang, T Sun, X Wang, Y Yin, Y Cheng, W Li, Y Gu, Q Chen, J Liu, J Cheng, C Geng, S Qin, S Wang, J Lu, K Shen, Q Liu, X Wang, H Wang, T Luo, J Yang, Y Wu, Z Yu, X Zhu, C Chen, J Zou
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.